Document is current
Any future updates will be listed below
-
Authors
Miao, Jing
Mehta, Ramila A.
Norby, Suzanne
Seide, Barbara
Milliner, Dawn S.
Lieske, John
Kattah, Andrea https://orcid.org/0000-0001-7228-9876
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases and National Center for Advancing Translational Sciences (U54-DK083908)
the Oxalosis & Hyperoxaluria Foundation
Mayo Foundation for Medical Education and Research
- License Information
-
More Information
Article History
Received: 7 January 2022
Accepted: 10 January 2022
First Online: 18 January 2022
Declarations
:
: Dr. Milliner: consulting fees paid to Mayo Foundation from OxThera, Alnylam, Dicerna, and Allena pharmaceutical companies. Research Grants from OxThera, Dicerna, and Alnylam. Dr. Lieske: consulting fees paid to Mayo Foundation from Alnylam, Dicerna, Synlogic, Orfan-Bridgebio, Novobiome, Federation Bio. Research Grants from Allena, Alnylam, OxThera, Dicerna, Synlogic.
: This study was approved by the Institutional Review Board of Mayo Clinic (Rochester, MN), and conducted in compliance with the approved protocols, good clinical practice guidelines, and all applicable regulatory requirements.
